Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 80/100

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

Monday, October 20, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced positive clinical updates, including the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and receiving IND approval from the US FDA to target B7H3. These developments mark significant progress in their clinical programs, reflecting the company's commitment to advancing innovative therapies.
Price reaction · baseline $5.7 (2025-10-20 close) · hit after-hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close
+6.3%
day 1
-5.2%
day 3 · peak
-6.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics received IND approval from the FDA.
  • The company has initiated a Phase 1/2a clinical study.
  • Positive updates were provided across four clinical programs.

Full Press Release Details

• Announcements , Updates
• PDF
• October 20, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• March 17, 2023
• Announcements
• September 13, 2024
• Announcements
• March 12, 2024
• Announcements
• October 31, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent updates did Radiopharm Theranostics announce?

Radiopharm announced positive clinical updates, including FDA IND approval and the initiation of a Phase 1/2a study for BetaBart.

What is the focus of the BetaBart clinical study?

The BetaBart clinical study targets B7H3 and aims to evaluate its therapeutic potential.

What phase is the BetaBart study currently in?

The BetaBart study is currently in Phase 1/2a.

Who was appointed to the Scientific Advisory Board?

Dr. Oliver Sartor was appointed to the Radiopharm Scientific Advisory Board.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA approval clinical study
Last updated: Oct 20, 2025